Galapagos, Ono Pharmaceutical deal

The BioFocus service division of Galapagos will use its SilenceSelect technology to discover validated targets for allergic diseases including atopic dermatitis and bronchial asthma for Ono. BioFocus will receive research funding and is eligible for milestones. Details were not disclosed. ...